Search

everythinglearnresearchcommunity

for

Search:↓

Clinical signs don't match inflammation levels in lichen planopilaris and frontal fibrosing alopecia.

High TSPEAR levels in colorectal cancer predict worse outcomes.

High TSPEAR levels in colorectal cancer predict worse outcomes.

Nanoparticle-based herbal remedies could be promising for treating hair loss with fewer side effects and lower cost, but more research is needed.

A chemical called 5-Bromo-2′-deoxyuridine caused rapid hair loss in mice by killing certain skin cells through a specific cell death pathway.

Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.

Mice treatments didn't grow hair, a patient treatment may affect immune response, and people with hair loss often feel anxious or depressed.

The document highlights various patents for new compounds with potential treatments for multiple diseases, including cancer, hormonal disorders, and diabetes.

Ovol2 is crucial for hair growth and skin healing by controlling cell movement and growth.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

CD80 on skin stem cells helps expand Treg cells to aid wound healing.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

IL-18 signaling helps mature Tregs move into the thymus.

Blocking certain immune signals can reduce skin damage from radiation therapy.

CD8+ T cells play a key role in graft-versus-host disease in certain mice models.

Alopecia areata involves unique activation of certain immune cells.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Basal cell carcinomas may use IDO to protect themselves from the immune system.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

CD206+ macrophages are crucial for hair growth in alopecia areata treatment.

Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

Super-enhancers control CD25 expression in specific cell types, affecting immune function.

Targeting specific T cells may help treat alopecia areata.

CD28 is a promising target for treating alopecia areata with belatacept.